Entera Bio (ENTX) Competitors $1.86 -0.05 (-2.62%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.83 -0.03 (-1.67%) As of 07/25/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. ARCT, GLUE, HUMA, CYRX, INBX, TNXP, FHTX, CADL, AURA, and ABEOShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), Humacyte (HUMA), CryoPort (CYRX), Inhibrx Biosciences (INBX), Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Candel Therapeutics (CADL), Aura Biosciences (AURA), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Its Competitors Arcturus Therapeutics Monte Rosa Therapeutics Humacyte CryoPort Inhibrx Biosciences Tonix Pharmaceuticals Foghorn Therapeutics Candel Therapeutics Aura Biosciences Abeona Therapeutics Arcturus Therapeutics (NASDAQ:ARCT) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation. Do analysts recommend ARCT or ENTX? Arcturus Therapeutics presently has a consensus target price of $54.00, indicating a potential upside of 261.45%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 437.63%. Given Entera Bio's higher possible upside, analysts plainly believe Entera Bio is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, ARCT or ENTX? Entera Bio has lower revenue, but higher earnings than Arcturus Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M2.66-$80.94M-$2.53-5.91Entera Bio$180K469.65-$9.54M-$0.26-7.15 Is ARCT or ENTX more profitable? Arcturus Therapeutics has a net margin of -47.47% compared to Entera Bio's net margin of -4,525.11%. Arcturus Therapeutics' return on equity of -27.41% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-47.47% -27.41% -19.01% Entera Bio -4,525.11%-95.10%-82.77% Which has more risk and volatility, ARCT or ENTX? Arcturus Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Do insiders and institutionals believe in ARCT or ENTX? 94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 16.6% of Arcturus Therapeutics shares are held by insiders. Comparatively, 10.4% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to ARCT or ENTX? In the previous week, Arcturus Therapeutics had 1 more articles in the media than Entera Bio. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Arcturus Therapeutics' score of 0.94 indicating that Entera Bio is being referred to more favorably in the news media. Company Overall Sentiment Arcturus Therapeutics Positive Entera Bio Very Positive SummaryArcturus Therapeutics beats Entera Bio on 12 of the 17 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.81M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-7.1521.1828.1020.05Price / Sales469.65286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book8.098.378.665.87Net Income-$9.54M-$55.19M$3.25B$258.55M7 Day Performance-9.27%5.88%4.22%3.73%1 Month Performance-6.77%17.33%10.51%11.75%1 Year Performance10.06%4.42%34.40%18.03% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio2.9185 of 5 stars$1.86-2.6%$10.00+437.6%+6.9%$86.81M$180K-7.1520Positive NewsARCTArcturus Therapeutics2.1609 of 5 stars$13.79+2.1%$54.00+291.6%-35.0%$366.13M$152.31M-5.45180GLUEMonte Rosa Therapeutics2.0218 of 5 stars$5.83-1.9%$15.33+163.0%+21.4%$365.37M$75.62M72.8890Gap UpHUMAHumacyte1.6488 of 5 stars$2.30-1.3%$11.71+409.3%-69.0%$361.43M$1.57M-3.33150News CoverageAnalyst ForecastCYRXCryoPort1.781 of 5 stars$6.71-6.7%$10.88+62.1%-12.4%$360.49M$228.38M-2.871,186Analyst ForecastInsider TradeINBXInhibrx Biosciences3.1615 of 5 stars$22.12-9.5%N/A+71.9%$353.94M$200K0.19166Positive NewsTNXPTonix Pharmaceuticals2.6031 of 5 stars$45.10-3.9%$585.00+1,197.1%-14.2%$345.13M$10.09M0.0050FHTXFoghorn Therapeutics2.142 of 5 stars$6.10-0.5%$12.13+98.8%-5.1%$341.70M$22.60M-4.49120News CoverageCADLCandel Therapeutics2.0909 of 5 stars$6.57-2.5%$22.00+234.9%+7.8%$337.69M$120K-4.9060AURAAura Biosciences2.4353 of 5 stars$6.77+0.9%$22.00+225.0%-29.6%$337.30MN/A-3.5650News CoveragePositive NewsABEOAbeona Therapeutics3.7543 of 5 stars$6.75+2.4%$19.25+185.2%+29.8%$337.12M$3.50M-5.3190 Related Companies and Tools Related Companies Arcturus Therapeutics Competitors Monte Rosa Therapeutics Competitors Humacyte Competitors CryoPort Competitors Inhibrx Biosciences Competitors Tonix Pharmaceuticals Competitors Foghorn Therapeutics Competitors Candel Therapeutics Competitors Aura Biosciences Competitors Abeona Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTX Stock Alerts